PepGen (NASDAQ:PEPG) Given New $20.00 Price Target at HC Wainwright

PepGen (NASDAQ:PEPG) had its price objective increased by HC Wainwright from $18.00 to $20.00 in a report released on Thursday,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for PepGen’s Q1 2026 earnings at ($0.52) EPS, Q2 2026 earnings at ($0.52) EPS, Q3 2026 earnings at ($0.52) EPS and Q4 2026 earnings at ($0.52) EPS.

A number of other brokerages also recently commented on PEPG. Guggenheim reissued a “buy” rating and issued a $6.00 price objective on shares of PepGen in a research report on Wednesday, September 24th. Stifel Nicolaus boosted their price target on PepGen from $9.00 to $12.00 and gave the stock a “buy” rating in a report on Thursday, September 25th. Wedbush boosted their price target on PepGen from $7.00 to $9.00 and gave the stock an “outperform” rating in a report on Thursday, September 25th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of PepGen in a report on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $10.00.

PepGen Price Performance

Shares of PepGen stock traded down $0.15 during trading on Thursday, hitting $4.74. 338,018 shares of the company were exchanged, compared to its average volume of 661,965. The firm’s fifty day moving average price is $4.00 and its 200 day moving average price is $2.28. The firm has a market capitalization of $155.47 million, a P/E ratio of -1.68 and a beta of 1.95. PepGen has a 1-year low of $0.88 and a 1-year high of $6.85.

PepGen (NASDAQ:PEPG) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.11. As a group, equities research analysts anticipate that PepGen will post -2.73 earnings per share for the current year.

Insiders Place Their Bets

In other news, major shareholder Science Enterprises Plc Oxford acquired 200,000 shares of the stock in a transaction that occurred on Tuesday, September 30th. The shares were acquired at an average cost of $3.20 per share, for a total transaction of $640,000.00. Following the purchase, the insider owned 4,955,388 shares of the company’s stock, valued at approximately $15,857,241.60. The trade was a 4.21% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 5.20% of the company’s stock.

Hedge Funds Weigh In On PepGen

A number of large investors have recently modified their holdings of the company. Viking Global Investors LP grew its stake in PepGen by 134.9% during the third quarter. Viking Global Investors LP now owns 3,482,434 shares of the company’s stock valued at $16,089,000 after acquiring an additional 2,000,000 shares in the last quarter. Deep Track Capital LP bought a new position in PepGen in the 3rd quarter valued at $5,544,000. Burkehill Global Management LP purchased a new position in shares of PepGen during the 3rd quarter valued at $46,000. ADAR1 Capital Management LLC raised its position in shares of PepGen by 81.0% in the third quarter. ADAR1 Capital Management LLC now owns 36,842 shares of the company’s stock worth $170,000 after buying an additional 16,490 shares in the last quarter. Finally, Two Sigma Investments LP boosted its stake in PepGen by 45.1% during the third quarter. Two Sigma Investments LP now owns 92,493 shares of the company’s stock valued at $427,000 after buying an additional 28,753 shares during the period. 58.01% of the stock is currently owned by institutional investors.

About PepGen

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.